Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs
- PMID: 22149932
- DOI: 10.1146/annurev-immunol-020711-075011
Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs
Abstract
Much has been learned about how cells enter lymphoid tissues. But how do they leave? Sphingosine-1-phosphate (S1P) has emerged over the past decade as a central mediator of lymphocyte egress. In this review, we summarize the current understanding of how S1P promotes exit from the secondary lymphoid organs and thymus. We review what is known about additional requirements for emigration and summarize the mostly distinct requirements for exit from the bone marrow. Egress from lymphoid organs is limited during immune responses, and we examine how this regulation works. There is accumulating evidence for roles of S1P in directing immune cell behavior within lymphoid tissues. How such actions can fit together with the egress-promoting role of S1P is discussed. Finally, we examine current understanding of how FTY720, a drug that targets S1P receptors and is approved for the treatment of multiple sclerosis, causes immune suppression.
Similar articles
-
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1.Nature. 2004 Jan 22;427(6972):355-60. doi: 10.1038/nature02284. Nature. 2004. PMID: 14737169
-
Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs.Annu Rev Immunol. 2005;23:127-59. doi: 10.1146/annurev.immunol.23.021704.115628. Annu Rev Immunol. 2005. PMID: 15771568 Review.
-
Sphingosine 1-phosphate receptor type 1 regulates egress of mature T cells from mouse bone marrow.Int Immunol. 2010 Jun;22(6):515-25. doi: 10.1093/intimm/dxq036. Epub 2010 May 23. Int Immunol. 2010. PMID: 20497959
-
Finding a way out: lymphocyte egress from lymphoid organs.Nat Immunol. 2007 Dec;8(12):1295-301. doi: 10.1038/ni1545. Nat Immunol. 2007. PMID: 18026082
-
FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.Pharmacol Ther. 2005 Dec;108(3):308-19. doi: 10.1016/j.pharmthera.2005.05.002. Epub 2005 Jun 13. Pharmacol Ther. 2005. PMID: 15951022 Review.
Cited by
-
Emerging Roles for Sphingolipids in Cardiometabolic Disease: A Rational Therapeutic Target?Nutrients. 2024 Sep 28;16(19):3296. doi: 10.3390/nu16193296. Nutrients. 2024. PMID: 39408263 Free PMC article. Review.
-
Proinflammatory immune cells disrupt angiogenesis and promote germinal matrix hemorrhage in prenatal human brain.Nat Neurosci. 2024 Nov;27(11):2115-2129. doi: 10.1038/s41593-024-01769-2. Epub 2024 Sep 30. Nat Neurosci. 2024. PMID: 39349662 Free PMC article.
-
Efficacy and safety of the S1PR modulator etrasimod in the treatment of moderately to severely active ulcerative colitis during the induction phase: a systematic review and meta-analysis of randomized controlled trials.Front Pharmacol. 2024 Sep 9;15:1420455. doi: 10.3389/fphar.2024.1420455. eCollection 2024. Front Pharmacol. 2024. PMID: 39314756 Free PMC article.
-
Sphingosine-1-Phosphate Receptor 4 links neutrophils and early local inflammation to lymphocyte recruitment into the draining lymph node to facilitate robust germinal center formation.Front Immunol. 2024 Aug 12;15:1427509. doi: 10.3389/fimmu.2024.1427509. eCollection 2024. Front Immunol. 2024. PMID: 39188715 Free PMC article.
-
New and emerging oral therapies for psoriasis.Drugs Context. 2024 Aug 1;13:2024-5-6. doi: 10.7573/dic.2024-5-6. eCollection 2024. Drugs Context. 2024. PMID: 39131603 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
